Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275–291 (2014).
Google Scholar
Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124–1134 (2017).
Google Scholar
Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
Google Scholar
Plaks, V., Kong, N. & Werb, Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16, 225–238 (2015).
Google Scholar
Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).
Google Scholar
Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).
Google Scholar
Al-Hajj, M. et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983–3988 (2003).
Google Scholar
Warrier, N. M. et al. Understanding cancer stem cells and plasticity: Towards better therapeutics. Eur. J. Cell Biol. 102, 151321 (2023).
Google Scholar
Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
Google Scholar
Lee, H. et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct. Target Ther. 10, 248 (2025).
Google Scholar
Kester, L. & van Oudenaarden, A. Single-cell transcriptomics meets lineage tracing. Cell Stem Cell 23, 166–179 (2018).
Google Scholar
Zhou, H. M., Zhang, J. G., Zhang, X. & Li, Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct. Target Ther. 6, 62 (2021).
Google Scholar
Philchenkov, A. & Dubrovska, A. Cancer stem cells as a therapeutic target: current clinical development and future prospective. Stem Cells 42, 173–199 (2024).
Google Scholar
Obisi, J. N. et al. Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations. Discov. Oncol. 16, 373 (2025).
Google Scholar
Capp, J. P. Cancer stem cells: from historical roots to a new perspective. J. Oncol. 2019, 5189232 (2019).
Google Scholar
Cicalese, A. et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138, 1083–1095 (2009).
Google Scholar
Dey-Guha, I. et al. Asymmetric cancer cell division regulated by AKT. Proc. Natl. Acad. Sci. USA 108, 12845–12850 (2011).
Google Scholar
Lan, X. et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 549, 227–232 (2017).
Google Scholar
Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608–611 (2009).
Google Scholar
Westphalen, C. B. et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J. Clin. Invest. 124, 1283–1295 (2014).
Google Scholar
Snippert, H. J. et al. Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion. EMBO Rep. 15, 62–69 (2014).
Google Scholar
Schepers, A. G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730–735 (2012).
Google Scholar
He, L. et al. Enhancing the precision of genetic lineage tracing using dual recombinases. Nat. Med. 23, 1488–1498 (2017).
Google Scholar
Alvarez-Aznar, A. et al. Tamoxifen-independent recombination of reporter genes limits lineage tracing and mosaic analysis using CreER(T2) lines. Transgenic Res. 29, 53–68 (2020).
Google Scholar
Tetteh, P. W. et al. Replacement of lost Lgr5-positive stem cells through plasticity of their enterocyte-lineage daughters. Cell Stem Cell 18, 203–213 (2016).
Google Scholar
Ceresa, D. et al. Early clonal extinction in glioblastoma progression revealed by genetic barcoding. Cancer Cell 41, 1466–1479.e9 (2023).
Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768–776 (2016).
Google Scholar
Reeves, M. Q. et al. Multicolour lineage tracing reveals clonal dynamics of squamous carcinoma evolution from initiation to metastasis. Nat. Cell Biol. 20, 699–709 (2018).
Google Scholar
Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633–644 (2011).
Google Scholar
Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510–523 (2010).
Google Scholar
Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 108, 7950–7955 (2011).
Google Scholar
Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487–1495 (2009).
Google Scholar
Batlle, E. et al. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84–89 (2000).
Google Scholar
Beck, B. et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 16, 67–79 (2015).
Google Scholar
Chaffer, C. L. et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61–74 (2013).
Google Scholar
Galassi, C. et al. Epigenetic regulation of cancer stemness. Signal Transduct. Target Ther. 10, 243 (2025).
Google Scholar
Dahan, P. et al. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis. 5, e1543 (2014).
Google Scholar
Lee, G. et al. Dedifferentiation of glioma cells to glioma stem-like cells by therapeutic stress-induced HIF signaling in the recurrent GBM model. Mol. Cancer Ther. 15, 3064–3076 (2016).
Google Scholar
Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468–476 (2010).
Google Scholar
Shimokawa, M. et al. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature 545, 187–192 (2017).
Google Scholar
Zhao, Y. et al. K-RAS acts as a critical regulator of CD44 to promote the invasiveness and stemness of GBM in response to ionizing radiation. Int J. Mol. Sci. 22, 10923 (2021).
Google Scholar
Peng, H. et al. Activin and hepatocyte growth factor promotes colorectal cancer stemness and metastasis through FOXM1/SOX2/CXCR4 signaling. Gut Liver 18, 476–488 (2024).
Google Scholar
Driessens, G. et al. Defining the mode of tumour growth by clonal analysis. Nature 488, 527–530 (2012).
Google Scholar
Yang, D. et al. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell 185, 1905–1923.e25 (2022).
de Sousa e Melo, F. et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature 543, 676–680 (2017).
Google Scholar
Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232–1251.e22 (2020).
Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25–38 (2013).
Google Scholar
Espinoza, F. I. et al. Targeting HIF-2alpha in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade. Cell Mol. Life Sci. 82, 119 (2025).
Google Scholar
Loh, J. J. & Ma, S. Hallmarks of cancer stemness. Cell Stem Cell 31, 617–639 (2024).
Google Scholar
Pastrana, E., Silva-Vargas, V. & Doetsch, F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8, 486–498 (2011).
Google Scholar
O’Flanagan, C. H. et al. Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. Genome Biol. 20, 210 (2019).
Google Scholar
Denisenko, E. et al. Systematic assessment of tissue dissociation and storage biases in single-cell and single-nucleus RNA-seq workflows. Genome Biol. 21, 130 (2020).
Google Scholar
Quan, Q. et al. Cancer stem-like cells with hybrid epithelial/mesenchymal phenotype leading the collective invasion. Cancer Sci. 111, 467–476 (2020).
Google Scholar
Fumagalli, A. et al. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell 26, 569–578.e7 (2020).
Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150–1162.e9 (2021).
Bhang, H. E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440–448 (2015).
Google Scholar
Quinn, J. J. et al. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science 371, eabc1944 (2021).
Google Scholar
Chu, X. et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct. Target Ther. 9, 170 (2024).
Google Scholar
Valle, S. et al. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. Nat. Commun. 11, 5265 (2020).
Google Scholar
Mascaraque, M. et al. Fatty acid oxidation is critical for the tumorigenic potential and chemoresistance of pancreatic cancer stem cells. J. Transl. Med. 22, 797 (2024).
Google Scholar
Nguyen, N. T. B. et al. Lactate controls cancer stemness and plasticity through epigenetic regulation. Cell Metab. 37, 903–919.e10 (2025).
Tien, P. C. et al. Notch signaling regulates a metabolic switch through inhibiting PGC-1alpha and mitochondrial biogenesis in dedifferentiated liposarcoma. Oncogene 42, 2521–2535 (2023).
Google Scholar
Vergara, D. et al. beta-Catenin knockdown affects mitochondrial biogenesis and lipid metabolism in breast cancer cells. Front Physiol. 8, 544 (2017).
Google Scholar
Sancho, P. et al. MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 22, 590–605 (2015).
Google Scholar
Sousa, C. M. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479–483 (2016).
Google Scholar
Kao, K. C., Vilbois, S., Tsai, C. H. & Ho, P. C. Metabolic communication in the tumour-immune microenvironment. Nat. Cell Biol. 24, 1574–1583 (2022).
Google Scholar
Ravi, V. M. et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell 40, 639–655.e13 (2022).
Hu, J. et al. Multi-transcriptomics reveals niche-specific expression programs and endothelial cells in glioblastoma. J. Transl. Med. 23, 444 (2025).
Google Scholar
Cao, L. et al. From single-cell to spatial transcriptomics: decoding the glioma stem cell niche and its clinical implications. Front Immunol. 15, 1475235 (2024).
Google Scholar
Walcher, L. et al. Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 11, 1280 (2020).
Google Scholar
Li, Y., Wang, Z., Ajani, J. A. & Song, S. Drug resistance and cancer stem cells. Cell Commun. Signal 19, 19 (2021).
Google Scholar
Asiedu, M. K. et al. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 71, 4707–4719 (2011).
Google Scholar
Iida, J. et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J. Invest Dermatol. 122, 167–176 (2004).
Google Scholar
Pang, R. et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6, 603–615 (2010).
Google Scholar
Liu, S. et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2, 78–91 (2014).
Google Scholar
Kessenbrock, K., Wang, C. Y. & Werb, Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol. 44-46, 184–190 (2015).
Google Scholar
Wang, C. et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell 28, 1597–1613.e7 (2021).
Fan, G. et al. Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways. Cancer. Cell. 44, 1160–1178.e8 (2026).
Miao, Y. et al. Adaptive immune resistance emerges from tumor-initiating stem cells. Cell 177, 1172–1186.e14 (2019).
Bakhshandeh, S. et al. Dormancy-inducing 3D engineered matrix uncovers mechanosensitive and drug-protective FHL2-p21 signaling axis. Sci. Adv. 10, eadr3997 (2024).
Google Scholar
Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628–632 (2014).
Google Scholar
Li, C. et al. Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling. Signal Transduct. Target Ther. 8, 247 (2023).
Google Scholar
Malladi, S. et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45–60 (2016).
Google Scholar
Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007).
Google Scholar
Chua, C. et al. Characterization of a side population of astrocytoma cells in response to temozolomide. J. Neurosurg. 109, 856–866 (2008).
Google Scholar
Tang, B. et al. A flexible reporter system for direct observation and isolation of cancer stem cells. Stem Cell Rep. 4, 155–169 (2015).
Google Scholar
Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–1037 (2007).
Google Scholar
Yang, Z. F. et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13, 153–166 (2008).
Google Scholar
Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
Google Scholar
O’Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).
Google Scholar
Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115 (2007).
Google Scholar
Shmelkov, S. V. et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118, 2111–2120 (2008).
Google Scholar
Abbasi, A. M. et al. CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells. Eur. J. Cancer 29A, 1995–2002 (1993).
Google Scholar
Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 104, 10158–10163 (2007).
Google Scholar
Todaro, M. et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342–356 (2014).
Google Scholar
Wielenga, V. J. et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 53, 4754–4756 (1993).
Google Scholar
Hirata, K. et al. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br. J. Cancer 109, 379–386 (2013).
Google Scholar
Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19, 387–400 (2011).
Google Scholar
Herlyn, M., Steplewski, Z., Herlyn, D. & Koprowski, H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc. Natl. Acad. Sci. USA 76, 1438–1442 (1979).
Google Scholar
Spizzo, G. et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J. Clin. Pathol. 64, 415–420 (2011).
Google Scholar
Ming, X. Y. et al. Integrin alpha7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma. Nat. Commun. 7, 13568 (2016).
Google Scholar
Haas, T. L. et al. Integrin alpha7 is a functional marker and potential therapeutic target in glioblastoma. Cell Stem Cell 21, 35–50.e9 (2017).
Wang, Y. et al. Spatial transcriptomics delineates molecular features and cellular plasticity in lung adenocarcinoma progression. Cell Discov. 9, 96 (2023).
Google Scholar
Nadalin, F. et al. Multi-omic lineage tracing predicts the transcriptional, epigenetic and genetic determinants of cancer evolution. Nat. Commun. 15, 7609 (2024).
Google Scholar
Burkhardt, D. B. et al. Mapping phenotypic plasticity upon the cancer cell state landscape using manifold learning. Cancer Discov. 12, 1847–1859 (2022).
Google Scholar
Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).
Google Scholar
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
Google Scholar
Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624.e24 (2017).
La Manno, G. et al. RNA velocity of single cells. Nature 560, 494–498 (2018).
Google Scholar
Tirosh, I. & Suva, M. L. Cancer cell states: lessons from ten years of single-cell RNA-sequencing of human tumors. Cancer Cell 42, 1497–1506 (2024).
Google Scholar
Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083–1086 (2017).
Google Scholar
Stoeckius, M. et al. Simultaneous epitope and transcriptome measurement in single cells. Nat. Methods 14, 865–868 (2017).
Google Scholar
Cao, J. et al. Joint profiling of chromatin accessibility and gene expression in thousands of single cells. Science 361, 1380–1385 (2018).
Google Scholar
Ma, S. et al. Chromatin potential identified by shared single-cell profiling of RNA and chromatin. Cell 183, 1103–1116.e20 (2020).
Haghverdi, L., Lun, A. T. L., Morgan, M. D. & Marioni, J. C. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol. 36, 421–427 (2018).
Google Scholar
Butler, A. et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
Google Scholar
Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281–291.e9 (2019).
McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329–337.e4 (2019).
Wagner, D. E. & Klein, A. M. Lineage tracing meets single-cell omics: opportunities and challenges. Nat. Rev. Genet. 21, 410–427 (2020).
Google Scholar
Stahl, P. L. et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science 353, 78–82 (2016).
Google Scholar
Rodriques, S. G. et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science 363, 1463–1467 (2019).
Google Scholar
Greenwald, A. C. et al. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. Cell 187, 2485–2501.e26 (2024).
Whittle, J. R. et al. Spatial omics shed light on the tumour organisation of glioblastoma. Semin Cell Dev. Biol. 167, 1–9 (2025).
Google Scholar
Eng, C. L. et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature 568, 235–239 (2019).
Google Scholar
Chen, K. H. et al. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 348, aaa6090 (2015).
Google Scholar
Goltsev, Y. et al. Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell 174, 968–981.e15 (2018).
Giesen, C. et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 11, 417–422 (2014).
Google Scholar
Keren, L. et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell 174, 1373–1387.e19 (2018).
de Souza, N., Zhao, S. & Bodenmiller, B. Multiplex protein imaging in tumour biology. Nat. Rev. Cancer 24, 171–191 (2024).
Google Scholar
Farin, H. F. et al. Visualization of a short-range Wnt gradient in the intestinal stem-cell niche. Nature 530, 340–343 (2016).
Google Scholar
Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522–526 (2012).
Google Scholar
Boyd, A. L. et al. Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence. Cancer Cell 34, 483–498.e5 (2018).
Caiado, F. et al. Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. Nat. Commun. 10, 4986 (2019).
Google Scholar
Merino, D. et al. Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nat. Commun. 10, 766 (2019).
Google Scholar
McKenna, A. et al. Whole-organism lineage tracing by combinatorial and cumulative genome editing. Science 353, aaf7907 (2016).
Google Scholar
McKenna, A. & Gagnon, J. A. Recording development with single cell dynamic lineage tracing. Development 146, dev169730 (2019).
Google Scholar
Pei, W. et al. Polylox barcoding reveals haematopoietic stem cell fates realized in vivo. Nature 548, 456–460 (2017).
Google Scholar
Lareau, C. A. et al. Mitochondrial single-cell ATAC-seq for high-throughput multi-omic detection of mitochondrial genotypes and chromatin accessibility. Nat. Protoc. 18, 1416–1440 (2023).
Google Scholar
Ludwig, L. S. et al. Lineage tracing in humans enabled by mitochondrial mutations and single-cell genomics. Cell 176, 1325–1339.e22 (2019).
Salvador-Martinez, I., Grillo, M., Averof, M. & Telford, M. J. Is it possible to reconstruct an accurate cell lineage using CRISPR recorders? Elife 8, e40292 (2019).
Google Scholar
Serrano, A., Berthelet, J., Naik, S. H. & Merino, D. Mastering the use of cellular barcoding to explore cancer heterogeneity. Nat. Rev. Cancer 22, 609–624 (2022).
Google Scholar
Leibovich, N. & Goyal, S. Limitations and optimizations of cellular lineages tracking. PLoS Comput. Biol. 21, e1012880 (2025).
Google Scholar
Aalam, S. M. M., Nguyen, L. V., Ritting, M. L. & Kannan, N. Clonal tracking in cancer and metastasis. Cancer Metastasis Rev. 43, 639–656 (2024).
Google Scholar
Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
Google Scholar
Matano, M. et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256–262 (2015).
Google Scholar
Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586–1598.e12 (2018).
Neal, J. T. et al. Organoid modeling of the tumor immune microenvironment. Cell 175, 1972–1988.e16 (2018).
Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer 18, 407–418 (2018).
Google Scholar
Xu, C. et al. Probabilistic harmonization and annotation of single-cell transcriptomics data with deep generative models. Mol. Syst. Biol. 17, e9620 (2021).
Google Scholar
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21 (2019).
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
Google Scholar
Lopez, R. et al. Deep generative modeling for single-cell transcriptomics. Nat. Methods 15, 1053–1058 (2018).
Google Scholar
Gayoso, A. et al. A Python library for probabilistic analysis of single-cell omics data. Nat. Biotechnol. 40, 163–166 (2022).
Google Scholar
Ergen, C. et al. Scvi-hub: an actionable repository for model-driven single-cell analysis. Nat. Methods 22, 1836–1845 (2025).
Google Scholar
Hu, J. et al. SpaGCN: Integrating gene expression, spatial location and histology to identify spatial domains and spatially variable genes by graph convolutional network. Nat. Methods 18, 1342–1351 (2021).
Google Scholar
Dong, K. & Zhang, S. Deciphering spatial domains from spatially resolved transcriptomics with an adaptive graph attention auto-encoder. Nat. Commun. 13, 1739 (2022).
Google Scholar
Zuo, C., Xia, J. & Chen, L. Dissecting tumor microenvironment from spatially resolved transcriptomics data by heterogeneous graph learning. Nat. Commun. 15, 5057 (2024).
Google Scholar
Lotfollahi, M. et al. Mapping single-cell data to reference atlases by transfer learning. Nat. Biotechnol. 40, 121–130 (2022).
Google Scholar
Hao, M. et al. STEM enables mapping of single-cell and spatial transcriptomics data with transfer learning. Commun. Biol. 7, 56 (2024).
Google Scholar
Wang, Z. et al. Comprehensive molecular characterization of high-stemness gastric cancer cells using single-cell transcriptomics, spatial mapping, and machine learning. NPJ Precis Oncol. 9, 400 (2025).
Google Scholar
Storrs, E. P. et al. High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. NPJ Precis Oncol. 7, 105 (2023).
Google Scholar
Zhang, Z. et al. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 14, 45 (2022).
Google Scholar
Wu, X., Que, H., Li, Q. & Wei, X. Wnt/beta-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy. Mol. Cancer 24, 171 (2025).
Google Scholar
Xu, X., Zhang, M., Xu, F. & Jiang, S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol. Cancer 19, 165 (2020).
Google Scholar
Zeng, Z. et al. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol. Cancer 22, 172 (2023).
Google Scholar
Liu, X. et al. Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/beta-catenin pathway. J. Exp. Clin. Cancer Res. 40, 132 (2021).
Google Scholar
Wang, J. et al. N6-Methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells’ properties and lenvatinib resistance through WNT/beta-catenin and Hippo signaling pathways. Gastroenterology 164, 990–1005 (2023).
Google Scholar
Alvarado-Ortiz, E. et al. Non-canonical Wnt co-receptors ROR1/ROR2 are differentially regulated by hypoxia in colon cancer cells. Biochim Biophys. Acta Mol. Cell Res. 1872, 119968 (2025).
Google Scholar
Wang, K. et al. WNT5a signaling through ROR2 activates the Hippo pathway to suppress YAP1 activity and tumor growth. Cancer Res. 83, 1016–1030 (2023).
Google Scholar
Wakizaka, K. et al. Expression of Wnt5a and ROR2, components of the noncanonical Wnt-signaling pathway, is associated with tumor differentiation in hepatocellular carcinoma. Ann. Surg. Oncol. 31, 262–271 (2024).
Google Scholar
He, Y. et al. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway. Mol. Cancer 20, 156 (2021).
Google Scholar
Xu, F., Wang, Y., Liang, R. & Jiang, S. Hsa_circ_0000467 promotes colorectal cancer proliferation and stem cell characteristics by activating the TCF4/Wnt/beta-catenin pathway via sponging miR-520g. APL Bioeng. 9, 026111 (2025).
Google Scholar
Deng, Z. et al. PNPO-mediated oxidation of DVL3 promotes multiple myeloma malignancy and osteoclastogenesis by activating the Wnt/beta-catenin pathway. Adv. Sci. 12, e2407681 (2025).
Google Scholar
Li, Y. et al. Transcription factor NFKB1 mediates TUBB6 to promote the proliferation and suppress apoptosis in glioma via Wnt/beta-catenin signaling pathway. Discov. Oncol. 16, 444 (2025).
Google Scholar
Zhang, W. et al. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/beta-catenin signaling pathway. Theranostics 12, 1500–1517 (2022).
Google Scholar
Kong, Y. et al. LGR6 promotes tumor proliferation and metastasis through Wnt/beta-catenin signaling in triple-negative breast cancer. Mol. Ther. Oncolytics 18, 351–359 (2020).
Google Scholar
Rong, Z. et al. SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling. Oncogene 41, 2390–2403 (2022).
Google Scholar
Eid, R. A. et al. Targeting cancer stem cells as the key driver of carcinogenesis and therapeutic resistance. Int. J. Mol. Sci. 24, 1786 (2023).
Google Scholar
Shi, Q. et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct. Target Ther. 9, 128 (2024).
Google Scholar
Yang, L. et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct. Target Ther. 5, 8 (2020).
Google Scholar
Tatarek, J. et al. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood 118, 1579–1590 (2011).
Google Scholar
Tamiro, F. et al. NOTCH1 dimeric signaling is essential for T-cell leukemogenesis and leukemia maintenance. Blood 145, 2887–2902 (2025).
Google Scholar
Liu, L. et al. Crosstalk between GLTSCR1-deficient endothelial cells and tumour cells promotes colorectal cancer development by activating the Notch pathway. Cell Death Differ. 32, 1231–1243 (2025).
Google Scholar
Majumder, M. et al. COX-2 induces breast cancer stem cells via EP4/PI3K/AKT/NOTCH/WNT axis. Stem Cells 34, 2290–2305 (2016).
Google Scholar
Ibrahim, S. A. et al. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol. Cancer 16, 57 (2017).
Google Scholar
Peng, J. et al. CD51 promotes gastric cancer stemness via blocking Numb-mediated Notch1 degradation. Cancer Lett. 629, 217886 (2025).
Google Scholar
Karthikeyan, S., Casey, P. J. & Wang, M. RAB4A is a master regulator of cancer cell stemness upstream of NUMB-NOTCH signaling. Cell Death Dis. 15, 778 (2024).
Google Scholar
Brabletz, S. et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 30, 770–782 (2011).
Google Scholar
Qiu, L. et al. HIST2H2BF potentiates the propagation of cancer stem cells via Notch signaling to promote malignancy and liver metastasis in colorectal carcinoma. Front Oncol. 11, 677646 (2021).
Google Scholar
Jin, L., Vu, T., Yuan, G. & Datta, P. K. STRAP promotes stemness of human colorectal cancer via epigenetic regulation of the NOTCH pathway. Cancer Res 77, 5464–5478 (2017).
Google Scholar
Briscoe, J. & Therond, P. P. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 14, 416–429 (2013).
Google Scholar
Cazet, A. S. et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat. Commun. 9, 2897 (2018).
Google Scholar
Jia, Y. et al. The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene 38, 1764–1777 (2019).
Google Scholar
Takebe, N. et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol. 12, 445–464 (2015).
Google Scholar
Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776–779 (2009).
Google Scholar
Regan, J. L. et al. Non-canonical Hedgehog signaling is a positive regulator of the WNT pathway and is required for the survival of colon cancer stem cells. Cell Rep. 21, 2813–2828 (2017).
Google Scholar
Liu, S. et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063–6071 (2006).
Google Scholar
Peacock, C. D. et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. USA 104, 4048–4053 (2007).
Google Scholar
Varnat, F. et al. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 1, 338–351 (2009).
Google Scholar
Justilien, V. et al. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 25, 139–151 (2014).
Google Scholar
Kim, B. R. et al. RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer. Cell Death Differ. 27, 676–694 (2020).
Google Scholar
Pandolfi, S. et al. WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function. Oncogene 32, 4737–4747 (2013).
Google Scholar
Zhou, M. et al. LncRNA-Hh strengthen cancer stem cells generation in twist-positive breast cancer via activation of Hedgehog signaling pathway. Stem Cells 34, 55–66 (2016).
Google Scholar
Yang, Z. J. et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 14, 135–145 (2008).
Google Scholar
Epstein, E. H. Basal cell carcinomas: attack of the hedgehog. Nat. Rev. Cancer 8, 743–754 (2008).
Google Scholar
Meng, Z. et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat. Commun. 6, 8357 (2015).
Google Scholar
Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759–772 (2011).
Google Scholar
Gregorieff, A. et al. Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. Nature 526, 715–718 (2015).
Google Scholar
Lai, D., Ho, K. C., Hao, Y. & Yang, X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 71, 2728–2738 (2011).
Google Scholar
Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet 47, 250–256 (2015).
Google Scholar
Guo, Q. et al. NF-kappaB in biology and targeted therapy: new insights and translational implications. Signal Transduct. Target Ther. 9, 53 (2024).
Google Scholar
England, F. J. et al. Sustained NF-kappaB activation allows mutant alveolar stem cells to co-opt a regeneration program for tumor initiation. Cell Stem Cell 32, 375–390.e9 (2025).
You, Q. et al. GJB2 enhances cancer stem cell properties by modulating SOX2 expression via NF-kappaB pathway activation in lung adenocarcinoma. Transl. Cancer Res. 14, 2648–2660 (2025).
Google Scholar
Li, D. et al. IFI35 regulates non-canonical NF-kappaB signaling to maintain glioblastoma stem cells and recruit tumor-associated macrophages. Cell Death Differ. 31, 738–752 (2024).
Google Scholar
Li, L. et al. Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway. Cancer Lett. 579, 216467 (2023).
Google Scholar
Wang, J. et al. Long noncoding RNA HOTAIR regulates the stemness of breast cancer cells via activation of the NF-kappaB signaling pathway. J. Biol. Chem. 298, 102630 (2022).
Google Scholar
Kim, S. L., Choi, H. S. & Lee, D. S. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells. Cell Commun. Signal 21, 315 (2023).
Google Scholar
Shen, P. et al. Yi Gong San inhibits tumor immune escape by sensitizing colorectal cancer stem cells via the NF-kappaB pathway. Hereditas 162, 64 (2025).
Google Scholar
Jiang, Y. X. et al. PFKFB3 regulates chemoresistance, metastasis and stemness via IAP proteins and the NF-kappaB signaling pathway in ovarian cancer. Front Oncol. 12, 748403 (2022).
Google Scholar
Zhao, B. et al. Inflammatory micro-environment contributes to stemness properties and metastatic potential of HCC via the NF-kappaB/miR-497/SALL4 axis. Mol. Ther. Oncolytics 15, 79–90 (2019).
Google Scholar
Bosman, M. C., Schuringa, J. J., Quax, W. J. & Vellenga, E. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-kappaB and the accumulation of MCL-1. Exp. Hematol. 41, 530–538.e1 (2013).
Li, Z. et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501–513 (2009).
Google Scholar
Bracken, C. P. et al. Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment. J. Biol. Chem. 281, 22575–22585 (2006).
Google Scholar
Tian, H. et al. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12, 3320–3324 (1998).
Google Scholar
Bhattacharya, R., Brown, J. S., Gatenby, R. A. & Ibrahim-Hashim, A. A gene for all seasons: the evolutionary consequences of HIF-1 in carcinogenesis, tumor growth and metastasis. Semin Cancer Biol. 102–103, 17–24 (2024).
Google Scholar
Man, J. et al. Hypoxic induction of vasorin regulates Notch1 turnover to maintain glioma stem-like cells. Cell Stem Cell 22, 104–118.e6 (2018).
Wu, K. et al. Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1alpha/Notch1 signaling pathway. Clin. Transl. Oncol. 25, 2138–2152 (2023).
Google Scholar
Miao, Z., Zhao, X. & Liu, X. Hypoxia induced beta-catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the wnt signaling pathway. Exp. Cell Res. 422, 113439 (2023).
Google Scholar
Li, X. et al. Hypoxia-induced lncRNA RBM5-AS1 promotes tumorigenesis via activating Wnt/beta-catenin signaling in breast cancer. Cell Death Dis. 13, 95 (2022).
Google Scholar
Liu, N. et al. Hypoxia differently regulates the proportion of ALDH(hi) cells in lung squamous carcinoma H520 and adenocarcinoma A549 cells via the Wnt/beta-catenin pathway. Thorac. Cancer 15, 1419–1428 (2024).
Google Scholar
Liu, D. et al. Hypoxia-induced galectin-8 maintains stemness in glioma stem cells via autophagy regulation. Neuro Oncol. 26, 872–888 (2024).
Google Scholar
Ye, C. et al. Hypoxia-induced HMGB1 promotes glioma stem cells self-renewal and tumorigenicity via RAGE. iScience 25, 104872 (2022).
Google Scholar
Lyu, Y. et al. Hypoxia-inducible factor 1 recruits FACT and RNF20/40 to mediate histone ubiquitination and transcriptional activation of target genes. Cell Rep. 43, 113972 (2024).
Google Scholar
Kakani, P. et al. Hypoxia-induced CTCF promotes EMT in breast cancer. Cell Rep. 43, 114367 (2024).
Google Scholar
He, X. C. et al. Hypoxia-induced one-carbon metabolic reprogramming in glioma stem-like cells. Life Med. 2, lnad048 (2023).
Google Scholar
Yang, Z. et al. Hypoxia inducible factor-1alpha drives cancer resistance to cuproptosis. Cancer Cell 43, 937–954.e9 (2025).
Dong, M. et al. Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages. Cancer Lett. 590, 216801 (2024).
Google Scholar
Nicholson, J. G. et al. Chronic hypoxia remodels the tumor microenvironment to support glioma stem cell growth. Acta Neuropathol. Commun. 12, 46 (2024).
Google Scholar
Kagan, V. E. et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81–90 (2017).
Google Scholar
Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism. Redox Biol., Dis. Cell. 171, 273–285 (2017).
Google Scholar
Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247–250 (2017).
Google Scholar
Shitara, K. et al. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407). Gastric Cancer 20, 1004–1009 (2017).
Google Scholar
Liu, C. C. et al. Esophageal cancer stem-like cells resist ferroptosis-induced cell death by active Hsp27-GPX4 pathway. Biomolecules 12, 48 (2021).
Google Scholar
Xu, X. et al. Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis. Eur. J. Pharm. Sci. 152, 105450 (2020).
Google Scholar
Tesfay, L. et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 79, 5355–5366 (2019).
Google Scholar
Magtanong, L. et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem. Biol. 26, 420–432.e9 (2019).
Wohlhieter, C. A. et al. Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer. Cell Rep. 33, 108444 (2020).
Google Scholar
Doll, S. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693–698 (2019).
Google Scholar
Mao, C. et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593, 586–590 (2021).
Google Scholar
Kraft, V. A. N. et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent. Sci. 6, 41–53 (2020).
Google Scholar
Kalkavan, H. et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell 185, 3356–3374.e22 (2022).
Banu, M. A. et al. A cell state-specific metabolic vulnerability to GPX4-dependent ferroptosis in glioblastoma. EMBO J. 43, 4492–4521 (2024).
Google Scholar
Caneque, T. et al. Activation of lysosomal iron triggers ferroptosis in cancer. Nature 642, 492–500 (2025).
Google Scholar
Sha, Y. et al. STUB1 regulates TFEB-induced autophagy-lysosome pathway. EMBO J. 36, 2544–2552 (2017).
Google Scholar
Auzmendi-Iriarte, J. et al. Chaperone-mediated autophagy controls proteomic and transcriptomic pathways to maintain glioma stem cell activity. Cancer Res. 82, 1283–1297 (2022).
Google Scholar
Radin, D. P. et al. Lucanthone targets lysosomes to perturb glioma proliferation, chemoresistance and stemness, and slows tumor growth in vivo. Front Oncol. 12, 852940 (2022).
Google Scholar
Martell, E. et al. Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations. Acta Neuropathol. Commun. 11, 110 (2023).
Google Scholar
Xing, Z. et al. Glutamine deprivation in glioblastoma stem cells triggers autophagic SIRT3 degradation to epigenetically restrict CD133 expression and stemness. Apoptosis 29, 1619–1631 (2024).
Google Scholar
Chen, Y. et al. Autophagy regulates the cancer stem cell phenotype of head and neck squamous cell carcinoma through the noncanonical FOXO3/SOX2 axis. Oncogene 41, 634–646 (2022).
Google Scholar
Peng, Q. et al. Astragalus polysaccharides sensitize ovarian cancer stem cells to PARPi by inhibiting mitophagy via PINK1/Parkin signaling. iScience 27, 110376 (2024).
Google Scholar
Phadte, P. et al. Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells. J. Exp. Clin. Cancer Res. 43, 222 (2024).
Google Scholar
Dykstra, K. M. et al. Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. Blood Adv. 5, 2087–2100 (2021).
Google Scholar
Derynck, R., Turley, S. J. & Akhurst, R. J. TGFbeta biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9–34 (2021).
Google Scholar
Kim, B. G. et al. Novel therapies emerging in oncology to target the TGF-beta pathway. J. Hematol. Oncol. 14, 55 (2021).
Google Scholar
Lo, P. K. et al. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene 31, 2614–2626 (2012).
Google Scholar
Katsuno, Y. et al. Chronic TGF-beta exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci. Signal 12, eaau8544 (2019).
Google Scholar
Yu, D., Shin, H. S., Lee, Y. S. & Lee, Y. C. miR-106b modulates cancer stem cell characteristics through TGF-beta/Smad signaling in CD44-positive gastric cancer cells. Lab Invest 94, 1370–1381 (2014).
Google Scholar
Stankic, M. et al. TGF-beta-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep. 5, 1228–1242 (2013).
Google Scholar
Bellomo, C., Caja, L. & Moustakas, A. Transforming growth factor beta as regulator of cancer stemness and metastasis. Br. J. Cancer 115, 761–769 (2016).
Google Scholar
Ishikawa, K. et al. Identification of quiescent LGR5(+) stem cells in the human colon. Gastroenterology 163, 1391–1406.e24 (2022).
Calon, A. et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571–584 (2012).
Google Scholar
Rasheed, Z. A. et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. Cancer Inst. 102, 340–351 (2010).
Google Scholar
Zhang, Y., Chen, Q., Chen, D. & Yang, G. Role of the TGF-beta/Smad3 pathway in pancreatic cancer cell growth and stem cell characteristics. Discov. Oncol. 16, 1480 (2025).
Google Scholar
Ikushima, H. et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5, 504–514 (2009).
Google Scholar
Wick, W., Platten, M. & Weller, M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J. Neurooncol. 53, 177–185 (2001).
Google Scholar
Sehgal, I. & Thompson, T. C. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol. Biol. Cell 10, 407–416 (1999).
Google Scholar
Lian, G. Y. et al. Inhibition of tumor invasion and metastasis by targeting TGF-beta-Smad-MMP2 pathway with Asiatic acid and Naringenin. Mol. Ther. Oncolytics 20, 277–289 (2021).
Google Scholar
Huang, W. et al. A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5. Neuro Oncol. 26, 85–99 (2024).
Google Scholar
Yin, J. et al. Cross-talk between PARN and EGFR-STAT3 signaling facilitates self-renewal and proliferation of glioblastoma stem cells. Cancer Res 83, 3693–3709 (2023).
Google Scholar
Fan, Q. W. et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 24, 438–449 (2013).
Google Scholar
Guo, G. et al. EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation. Nat. Cell Biol. 24, 1291–1305 (2022).
Google Scholar
Lv, D. et al. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma. Mol. Cell 83, 4334–4351.e7 (2023).
Lv, D. et al. PDGF signaling inhibits mitophagy in glioblastoma stem cells through N(6)-methyladenosine. Dev. Cell 57, 1466–1481.e6 (2022).
Sadahiro, H. et al. Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma. Cancer Res. 78, 3002–3013 (2018).
Google Scholar
Engelsen, A. S. T. et al. AXL is a driver of stemness in normal mammary gland and breast cancer. iScience 23, 101649 (2020).
Google Scholar
Cheng, P. et al. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Rep. 4, 899–913 (2015).
Google Scholar
Hu, H. et al. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell 175, 1665–1678.e18 (2018).
Junca, A. et al. Crizotinib targets in glioblastoma stem cells. Cancer Med. 6, 2625–2634 (2017).
Google Scholar
Binda, E. et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22, 765–780 (2012).
Google Scholar
Cui, X. et al. Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma. Cancer Commun. 43, 1326–1353 (2023).
Google Scholar
Zhang, G. et al. Dissecting the spatial and single-cell transcriptomic architecture of cancer stem cell niche driving tumor progression in gastric cancer. Adv. Sci. 12, e2413019 (2025).
Google Scholar
Alvarez-Vazquez, A. et al. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models. Neuro Oncol. 26, 1230–1246 (2024).
Google Scholar
Lee, J. S. et al. The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2/PI3K-mediated regulation of MYC. Cell Rep. 41, 111759 (2022).
Google Scholar
Chan, Y. T. et al. The interplay between IGF-1R signaling and Hippo-YAP in breast cancer stem cells. Cell Commun. Signal 21, 81 (2023).
Google Scholar
Lopez-Cerda, M. et al. IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinoma. J. Exp. Clin. Cancer Res. 43, 211 (2024).
Google Scholar
Wu, H. et al. IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma. Cell Death Discov. 10, 102 (2024).
Google Scholar
Tian, Q. et al. IGF1/IGF1R signaling promotes the expansion of liver CSCs and serves as a potential therapeutic target in HCC. Discov. Oncol. 16, 1058 (2025).
Google Scholar
Rattanasinchai, C., Navasumrit, P., Chornkrathok, C. & Ruchirawat, M. Kinase library screening identifies IGF-1R as an oncogenic vulnerability in intrahepatic cholangiocarcinoma stem-like cells. Biochim. Biophys. Acta Mol. Basis Dis. 1871, 167521 (2025).
Google Scholar
Osuka, S. et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells 31, 627–640 (2013).
Google Scholar
Ramakrishnan, V. et al. Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas. EBioMedicine 55, 102736 (2020).
Google Scholar
Kazi, J. U. & Ronnstrand, L. FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications. Physiol. Rev. 99, 1433–1466 (2019).
Google Scholar
Gilliland, D. G. & Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100, 1532–1542 (2002).
Google Scholar
Yoshimoto, G. et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114, 5034–5043 (2009).
Google Scholar
Araujo, J. L. et al. FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells. Blood 145, 2361–2373 (2025).
Google Scholar
Cauchy, P. et al. Chronic FLT3-ITD signaling in acute myeloid leukemia is connected to a specific chromatin signature. Cell Rep. 12, 821–836 (2015).
Google Scholar
Qiu, S. et al. Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition. Leukemia 36, 2621–2633 (2022).
Google Scholar
Leong, K. G., Wang, B. E., Johnson, L. & Gao, W. Q. Generation of a prostate from a single adult stem cell. Nature 456, 804–808 (2008).
Google Scholar
Foster, B. M. et al. CD117/c-kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines 6, 31 (2018).
Google Scholar
Theou-Anton, N. et al. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br. J. Cancer 94, 1180–1185 (2006).
Google Scholar
Zhang, D. et al. Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor. BMC Med. 20, 257 (2022).
Google Scholar
Lennartsson, J. & Ronnstrand, L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol. Rev. 92, 1619–1649 (2012).
Google Scholar
Parker, P. J. et al. Equivocal, explicit and emergent actions of PKC isoforms in cancer. Nat. Rev. Cancer 21, 51–63 (2021).
Google Scholar
Blume-Jensen, P., Wernstedt, C., Heldin, C. H. & Ronnstrand, L. Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells. J. Biol. Chem. 270, 14192–14200 (1995).
Google Scholar
Loftus, A. E. P. et al. An ILK/STAT3 pathway controls glioblastoma stem cell plasticity. Dev. Cell 59, 3197–3212.e7 (2024).
Sharanek, A. et al. Transcriptional control of brain tumor stem cells by a carbohydrate binding protein. Cell Rep. 36, 109647 (2021).
Google Scholar
Shi, Y. et al. Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. Sci. Transl. Med. 10, eaah6816 (2018).
Google Scholar
Ma, Y. et al. LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling. Oncogene 42, 1419–1437 (2023).
Google Scholar
Lee, C. H. et al. MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer. Breast Cancer Res. 27, 136 (2025).
Google Scholar
Li, K. et al. AKAP12 promotes cancer stem cell-like phenotypes and activates STAT3 in colorectal cancer. Clin. Transl. Oncol. 25, 3263–3276 (2023).
Google Scholar
Gao, Q. et al. E2F3 accelerates the stemness of colon cancer cells by activating the STAT3 pathway. Front Oncol. 13, 1203712 (2023).
Google Scholar
Tian, Y. et al. An IL-6-induced STAT3-to-PI3K signaling switch potently drives PD-L1 transcription in cancer stem cells of colorectal cancer. Sci. Bull. 71, 273–277 (2026).
Google Scholar
Zhang, E. et al. NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling. J. Transl. Med. 22, 12 (2024).
Google Scholar
Tremblay, C. S. et al. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia. Blood 142, 274–289 (2023).
Google Scholar
Li, Y. et al. Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia. Stem Cell Rep. 19, 100–111 (2024).
Google Scholar
Sessions, D. T. & Kashatus, D. F. Mitochondrial dynamics in cancer stem cells. Cell Mol. Life Sci. 78, 3803–3816 (2021).
Google Scholar
Chen, H. & Chan, D. C. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. Cell Metab. 26, 39–48 (2017).
Google Scholar
Pei, S. et al. AMPK/FIS1-mediated mitophagy is required for self-renewal of human AML stem cells. Cell Stem Cell 23, 86–100.e6 (2018).
Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780–783 (2009).
Google Scholar
Giannitti, G. et al. Unraveling the role of mitochondrial dynamics in cancer stem cells: molecular basis and therapeutic implications. Biochim Biophys. Acta Rev. Cancer 1880, 189450 (2025).
Google Scholar
Liu, Z. et al. Lipogenesis promotes mitochondrial fusion and maintains cancer stemness in human NSCLC. JCI Insight 8, e158429 (2023).
Google Scholar
Yao, C. H. et al. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. Elife 8, e41351 (2019).
Google Scholar
Fontana, F. et al. PGC1-alpha-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 166897 (2024).
Google Scholar
Xie, Q. et al. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat. Neurosci. 18, 501–510 (2015).
Google Scholar
Sun, F. et al. CAMK1D activates AMPK/PINK1/Parkin-dependent mitophagy to promote enzalutamide resistance in prostate cancer. Cell Death Dis. 17, 113 (2026).
Google Scholar
Rouault, C. D., Charafe-Jauffret, E. & Ginestier, C. The interplay of DNA damage, epigenetics and tumour heterogeneity in driving cancer cell fitness. Nat. Commun. 16, 8733 (2025).
Google Scholar
Chen, X. et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 13, 974 (2022).
Google Scholar
Marei, H. E. Epigenetic regulators in cancer therapy and progression. NPJ Precis Oncol. 9, 206 (2025).
Google Scholar
Song, J. et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct. Target Ther. 10, 219 (2025).
Google Scholar
Easwaran, H., Tsai, H. C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716–727 (2014).
Google Scholar
Wainwright, E. N. & Scaffidi, P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer 3, 372–386 (2017).
Google Scholar
Zheng, X., Yu, C. & Xu, M. Linking tumor microenvironment to plasticity of cancer stem cells: mechanisms and application in cancer therapy. Front Oncol. 11, 678333 (2021).
Google Scholar
Maugeri-Sacca, M., Bartucci, M. & De Maria, R. DNA damage repair pathways in cancer stem cells. Mol. Cancer Ther. 11, 1627–1636 (2012).
Google Scholar
Phi, L. T. H. et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018, 5416923 (2018).
Google Scholar
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Google Scholar
Alsubhi, N. et al. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Mol. Oncol. 10, 213–223 (2016).
Google Scholar
Tuy, K., Rickenbacker, L. & Hjelmeland, A. B. Reactive oxygen species produced by altered tumor metabolism impacts cancer stem cell maintenance. Redox Biol. 44, 101953 (2021).
Google Scholar
Choi, H. J. et al. FoxM1-dependent and fatty acid oxidation-mediated ROS modulation is a cell-intrinsic drug resistance mechanism in cancer stem-like cells. Redox Biol. 36, 101589 (2020).
Google Scholar
Chen, K. et al. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance. Cell Death Dis. 12, 835 (2021).
Google Scholar
Pajonk, F., Vlashi, E. & McBride, W. H. Radiation resistance of cancer stem cells: the 4 R’s of radiobiology revisited. Stem Cells 28, 639–648 (2010).
Google Scholar
Lin, J. C. et al. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties. Radiother. Oncol. 129, 352–363 (2018).
Google Scholar
Hallis, S. P., Kim, J. M. & Kwak, M. K. Emerging role of NRF2 signaling in cancer stem cell phenotype. Mol. Cells 46, 153–164 (2023).
Google Scholar
Son, Y. W., Cheon, M. G., Kim, Y. & Jang, H. H. Prx2 links ROS homeostasis to stemness of cancer stem cells. Free Radic. Biol. Med. 134, 260–267 (2019).
Google Scholar
Karabicici, M., Alptekin, S., Firtina Karagonlar, Z. & Erdal, E. Doxorubicin-induced senescence promotes stemness and tumorigenicity in EpCAM-/CD133- nonstem cell population in hepatocellular carcinoma cell line, HuH-7. Mol. Oncol. 15, 2185–2202 (2021).
Google Scholar
Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013).
Google Scholar
Huang, C. P. et al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 328, 144–151 (2013).
Google Scholar
Corominas-Faja, B. et al. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle 12, 3390–3404 (2013).
Google Scholar
Sullivan, J. P. et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 70, 9937–9948 (2010).
Google Scholar
Kudaravalli, S., den Hollander, P. & Mani, S. A. Role of p38 MAP kinase in cancer stem cells and metastasis. Oncogene 41, 3177–3185 (2022).
Google Scholar
Huang, Y., Hong, W. & Wei, X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J. Hematol. Oncol. 15, 129 (2022).
Google Scholar
Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet 44, 852–860 (2012).
Google Scholar
Gjerdrum, C. et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. USA 107, 1124–1129 (2010).
Google Scholar
Giles, K. M. et al. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther. 12, 2541–2558 (2013).
Google Scholar
Wang, J. et al. The role of stromal cells in epithelial-mesenchymal plasticity and its therapeutic potential. Discov. Oncol. 15, 13 (2024).
Google Scholar
Farmer, P. et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15, 68–74 (2009).
Google Scholar
Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 107, 15449–15454 (2010).
Google Scholar
Noman, M. Z. et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology 6, e1263412 (2017).
Google Scholar
Chen, L. et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun. 5, 5241 (2014).
Google Scholar
Li, N. et al. An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis 8, 13 (2019).
Google Scholar
Ghatak, S., Hascall, V. C., Markwald, R. R. & Misra, S. FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells. Int. J. Mol. Sci. 22, 753 (2021).
Google Scholar
Levin, T. G. et al. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology 139, 2072–2082.e5 (2010).
Kim, D. K. et al. CD166 promotes the cancer stem-like properties of primary epithelial ovarian cancer cells. BMB Rep. 53, 622–627 (2020).
Google Scholar
Gomez-Miragaya, J. & Gonzalez-Suarez, E. Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer. Mol. Cell Oncol. 4, e1338208 (2017).
Google Scholar
Gomez-Miragaya, J. et al. Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population. Stem Cell Rep. 8, 1392–1407 (2017).
Google Scholar
Jang, Y. et al. CD24 induced cellular quiescence-like state and chemoresistance in ovarian cancer cells via miR-130a/301a-dependent CDK19 downregulation. Cell Death Discov. 10, 81 (2024).
Google Scholar
Liu, Y. et al. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia. Stem Cell Res. Ther. 12, 86 (2021).
Google Scholar
Leung, K. T. et al. CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity. Leukemia 34, 709–720 (2020).
Google Scholar
Roy, S. et al. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma. J. Oral. Pathol. Med. 47, 492–501 (2018).
Google Scholar
Phan, T. G. & Croucher, P. I. The dormant cancer cell life cycle. Nat. Rev. Cancer 20, 398–411 (2020).
Google Scholar
Sosa, M. S., Bragado, P. & Aguirre-Ghiso, J. A. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat. Rev. Cancer 14, 611–622 (2014).
Google Scholar
Francescangeli, F. et al. A pre-existing population of ZEB2(+) quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. J. Exp. Clin. Cancer Res. 39, 2 (2020).
Google Scholar
Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319–325 (2002).
Google Scholar
Dembinski, J. L. & Krauss, S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin. Exp. Metastasis 26, 611–623 (2009).
Google Scholar
Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583–594 (2010).
Google Scholar
Nayak, A., Warrier, N. M. & Kumar, P. Cancer stem cells and the tumor microenvironment: targeting the critical crosstalk through nanocarrier systems. Stem Cell Rev. Rep. 18, 2209–2233 (2022).
Google Scholar
Soeda, A. et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28, 3949–3959 (2009).
Google Scholar
Akakura, N. et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 61, 6548–6554 (2001).
Google Scholar
Rausch, V. et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J. Pathol. 227, 325–335 (2012).
Google Scholar
Chen, G. et al. Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA. Oncogenesis 9, 81 (2020).
Google Scholar
Ruivo, C. F. et al. Extracellular vesicles from pancreatic cancer stem cells lead an intratumor communication network (EVNet) to fuel tumour progression. Gut 71, 2043–2068 (2022).
Google Scholar
Li, J. et al. Hypoxic glioma stem cell-derived exosomes containing Linc01060 promote progression of glioma by regulating the MZF1/c-Myc/HIF1alpha axis. Cancer Res. 81, 114–128 (2021).
Google Scholar
Yin, J. et al. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. Theranostics 11, 1763–1779 (2021).
Google Scholar
Rolver, M. G. et al. Tumor microenvironment acidosis favors pancreatic cancer stem cell properties and in vivo metastasis. iScience 28, 111956 (2025).
Google Scholar
Lin, Y. et al. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Hepatology 75, 28–42 (2022).
Google Scholar
Huang, R. et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating beta-catenin/STAT3 signaling. Cell Death Dis. 11, 234 (2020).
Google Scholar
Chen, X. et al. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/beta-catenin signaling. Cell Commun. Signal 20, 92 (2022).
Google Scholar
You, Y. et al. M1-like tumor-associated macrophages cascade a mesenchymal/stem-like phenotype of oral squamous cell carcinoma via the IL6/Stat3/THBS1 feedback loop. J. Exp. Clin. Cancer Res. 41, 10 (2022).
Google Scholar
Yuan, Y. et al. Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8(+) T cells. Cancer Lett. 500, 98–106 (2021).
Google Scholar
Kim, M. et al. Re-sensitizing cancer stem cells to conventional chemotherapy agents. Int. J. Mol. Sci. 24, 2122 (2023).
Google Scholar
Xie, M., He, C. S., Wei, S. H. & Zhang, L. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur. J. Cancer 49, 3559–3572 (2013).
Google Scholar
McAuliffe, S. M. et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl. Acad. Sci. USA 109, E2939–E2948 (2012).
Google Scholar
Arensman, M. D. et al. WNT7B mediates autocrine Wnt/beta-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Oncogene 33, 899–908 (2014).
Google Scholar
Gorojankina, T. Hedgehog signaling pathway: a novel model and molecular mechanisms of signal transduction. Cell Mol. Life Sci. 73, 1317–1332 (2016).
Google Scholar
Sims-Mourtada, J., Izzo, J. G., Ajani, J. & Chao, K. S. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26, 5674–5679 (2007).
Google Scholar
Kuo, Y. C. et al. Identification and clinical significance of pancreatic cancer stem cells and their chemotherapeutic drug resistance. Int. J. Mol. Sci. 24, 7331 (2023).
Google Scholar
Doubre, H. et al. Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int. J. Cancer 113, 568–574 (2005).
Google Scholar
Vaidyanathan, A. et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br. J. Cancer 115, 431–441 (2016).
Google Scholar
Wei, Y. et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc. Natl. Acad. Sci. USA 110, 6829–6834 (2013).
Google Scholar
Langhans, J. et al. The effects of PI3K-mediated signalling on glioblastoma cell behaviour. Oncogenesis 6, 398 (2017).
Google Scholar
Liu, S. & Cheng, C. Akt signaling is sustained by a CD44 splice isoform-mediated positive feedback loop. Cancer Res. 77, 3791–3801 (2017).
Google Scholar
Formenti, S. C. et al. Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. J. Immunother. Cancer 7, 177 (2019).
Google Scholar
Formenti, S. C. et al. Focal irradiation and systemic TGFbeta blockade in metastatic breast cancer. Clin. Cancer Res. 24, 2493–2504 (2018).
Google Scholar
Joosten, S. P. J. et al. MET signaling overcomes epidermal growth factor receptor inhibition in normal and colorectal cancer stem cells causing drug resistance. Gastroenterology 157, 1153–1155.e1 (2019).
De Bacco, F. et al. MET inhibition overcomes radiation resistance of glioblastoma stem-like cells. EMBO Mol. Med. 8, 550–568 (2016).
Google Scholar
Wei, T. T. et al. Metabolic targeting of HIF-1alpha potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer. Oncogene 39, 414–427 (2020).
Google Scholar
Lu, Z., Yao, X., Jiang, J. & Hou, G. ERCC6L-mediated stabilization of HIF-1alpha enhances glycolysis and stemness properties of lung adenocarcinoma cells. Cell Death Dis. 16, 541 (2025).
Google Scholar
LoConte, N. K. et al. A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest N. Drugs 33, 169–176 (2015).
Google Scholar
Ran, Y. et al. gamma-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol. Med. 9, 950–966 (2017).
Google Scholar
Ju, F. et al. Characteristics of the cancer stem cell niche and therapeutic strategies. Stem Cell Res. Ther. 13, 233 (2022).
Google Scholar
Proffitt, K. D. et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 73, 502–507 (2013).
Google Scholar
Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).
Google Scholar
Zheng, F. et al. Cancer stem cell vaccination with PD-L1 and CTLA-4 blockades enhances the eradication of melanoma stem cells in a mouse tumor model. J. Immunother. 41, 361–368 (2018).
Google Scholar
Wang, K. et al. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells. Cancer Cell 42, 1582–1597.e10 (2024).
Wojtukiewicz, M. Z. et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 40, 949–982 (2021).
Google Scholar
Wu, K. et al. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Exp. Hematol. Oncol. 8, 26 (2019).
Google Scholar
Daimon, T. et al. MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells. Cell Death Discov. 10, 9 (2024).
Google Scholar
Mao, X. et al. Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway. J. Nat. Med. 75, 590–601 (2021).
Google Scholar
Shi, Y. et al. Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling. Front Oncol. 15, 1631415 (2025).
Google Scholar
Seguin, L., Gozo, M., Weis, S. M. & Cheresh, D. A. Targeting the Achilles’ heel of drug-resistant cancer stem cells. Cell Cycle 13, 2017–2018 (2014).
Google Scholar
Dotan, E. et al. Phase Ib study of Wnt inhibitor ipafricept with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer. Clin. Cancer Res. 26, 5348–5357 (2020).
Google Scholar
Moore, K. N. et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol. Oncol. 154, 294–301 (2019).
Google Scholar
Shah, M. A. et al. Randomized, double-blind, placebo-controlled phase III study of paclitaxel +/- napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. Clin. Cancer Res. 28, OF1–OF9 (2022).
Google Scholar
Huang, J. et al. A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma. Int J. Radiat. Oncol. Biol. Phys. 120, 738–749 (2024).
Google Scholar
Werlenius, K. et al. Effect of disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma: a randomized clinical trial. JAMA Netw. Open 6, e234149 (2023).
Google Scholar
Toledo-Guzman, M. E., Hernandez, M. I., Gomez-Gallegos, A. A. & Ortiz-Sanchez, E. ALDH as a stem cell marker in solid tumors. Curr. Stem Cell Res. Ther. 14, 375–388 (2019).
Google Scholar
Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320–1329 (2024).
Google Scholar
Schmidts, A. et al. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Ralpha2 are effective against heterogeneous glioblastoma. Neurooncol. Adv. 5, vdac185 (2023).
Google Scholar
Wang, Y. et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology 7, e1440169 (2018).
Google Scholar
Rudnick, J. D. et al. Immunological targeting of CD133 in recurrent glioblastoma: a multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy. J. Clin. Oncol. 35, 2059–2059 (2017).
Google Scholar
Burges, A. et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin. Cancer Res. 13, 3899–3905 (2007).
Google Scholar
Herpers, B. et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR x LGR5 bispecific antibody with efficacy in epithelial tumors. Nat. Cancer 3, 418–436 (2022).
Google Scholar
Machiels, J. P. et al. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 21, 2007–2016 (2025).
Google Scholar
Dorff, T. B. et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 30, 1636–1644 (2024).
Google Scholar
Lin, M. et al. Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. J. Cancer Res. Clin. Oncol. 141, 1827–1833 (2015).
Google Scholar
Wen, P. Y. et al. A Randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin. Cancer Res. 25, 5799–5807 (2019).
Google Scholar
Schuhmacher, J. et al. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. J. Immunother. Cancer 8, e001157 (2020).
Google Scholar
Vik-Mo, E. O. et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol. Immunother. 62, 1499–1509 (2013).
Google Scholar
Lee, H. W. et al. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 12, 47 (2020).
Google Scholar
Feng, T. et al. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study. J. Immunother. Cancer 12, e008942 (2024).
Google Scholar
He, S., Zheng, L. & Qi, C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol. Cancer 24, 5 (2025).
Google Scholar
Clara, J. A., Monge, C., Yang, Y. & Takebe, N. Targeting signalling pathways and the immune microenvironment of cancer stem cells – a clinical update. Nat. Rev. Clin. Oncol. 17, 204–232 (2020).
Google Scholar
Voissiere, A. et al. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Sci. Transl. Med. 16, eadd1834 (2024).
Google Scholar
Xu, J. et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct. Target Ther. 10, 268 (2025).
Google Scholar
Hong, D. S. et al. Mogamulizumab in combination with nivolumab in a phase I/II study of patients with locally advanced or metastatic solid tumors. Clin. Cancer Res. 28, 479–488 (2022).
Google Scholar
Jinushi, K. et al. Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors. J. Immunother. Cancer 13, e010634 (2025).
Google Scholar
Hanna, G. J. et al. A phase I study of the Pan-Notch inhibitor CB-103 for patients with advanced adenoid cystic carcinoma and other tumors. Cancer Res. Commun. 3, 1853–1861 (2023).
Google Scholar
Even, C. et al. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest N. Drugs 38, 402–409 (2020).
Google Scholar
De Jesus-Acosta, A. et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br. J. Cancer 122, 498–505 (2020).
Google Scholar
Tang, J. Y. et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N. Engl. J. Med. 366, 2180–2188 (2012).
Google Scholar
Gounder, M. et al. Nirogacestat, a gamma-secretase inhibitor for desmoid tumors. N. Engl. J. Med. 388, 898–912 (2023).
Google Scholar
Jiang, G. et al. Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression. Cell Death Dis. 12, 979 (2021).
Google Scholar
Mo, S. et al. Patient-derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy. Adv. Sci. 9, e2204097 (2022).
Google Scholar
Han, J. et al. Bioprinted patient-derived organoid arrays capture intrinsic and extrinsic tumor features for advanced personalized medicine. Adv. Sci. 12, e2407871 (2025).
Google Scholar
Anderko, R. R. et al. Pancreatic cancer organoids recapitulate chemotherapy response and identify a potent cytotoxic T cell population. Clin. Cancer Res. 32, 596–610 (2026).
Google Scholar
Ricardo, S. et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 64, 937–946 (2011).
Google Scholar
Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62–73 (2010).
Google Scholar
Azizi, Z., Er Urganci, B. & Acikbas, I. Breast cancer stem cells and circulating tumor cells: Dual drivers of progression and relapse. World J. Stem Cells 17, 112990 (2025).
Google Scholar
Son, M. J. et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4, 440–452 (2009).
Google Scholar
Tang, X. et al. Targeting glioblastoma stem cells: a review on biomarkers, signal pathways and targeted therapy. Front Oncol. 11, 701291 (2021).
Google Scholar
Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821–5828 (2003).
Google Scholar
Galdieri, L. et al. Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. JCI Insight 6, e128456 (2021).
Google Scholar
Eramo, A. et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504–514 (2008).
Google Scholar
Zheng, Y. et al. Lung cancer stem cell markers as therapeutic targets: an update on signaling pathways and therapies. Front Oncol. 12, 873994 (2022).
Google Scholar
Prabavathy, D., Swarnalatha, Y. & Ramadoss, N. Lung cancer stem cells—origin, characteristics and therapy. Stem Cell Investig. 5, 6 (2018).
Google Scholar
Duan, Y. et al. Colorectal cancer stem cells crosstalk in tumor immune microenvironment and targeted therapeutic strategies. Front Immunol. 16, 1714954 (2025).
Google Scholar
Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313–323 (2007).
Google Scholar
Heiler, S., Wang, Z. & Zoller, M. Pancreatic cancer stem cell markers and exosomes—the incentive push. World J. Gastroenterol. 22, 5971–6007 (2016).
Google Scholar
Lu, J. O. D. C., Tsui, Y. M. & Ng, I. O. Cancer stem cells in hepatocellular carcinoma: platforms, updates, challenges and future perspectives. Cancer Biol. Med. 23, 1–7 (2025).
Google Scholar
Liu, S. et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology 144, 1031–1041.e10 (2013).
Tsui, Y. M., Chan, L. K. & Ng, I. O. Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. Br. J. Cancer 122, 1428–1440 (2020).
Google Scholar
Haraguchi, N. et al. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 120, 3326–3339 (2010).
Google Scholar
Collins, A. T. et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946–10951 (2005).
Google Scholar
Patrawala, L. et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25, 1696–1708 (2006).
Google Scholar
van den Hoogen, C. et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 70, 5163–5173 (2010).
Google Scholar
Ugolkov, A. V., Eisengart, L. J., Luan, C. & Yang, X. J. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 71, 18–25 (2011).
Google Scholar
Harris, K. S. & Kerr, B. A. Prostate cancer stem cell markers drive progression, therapeutic resistance, and bone metastasis. Stem Cells Int. 2017, 8629234 (2017).
Google Scholar
Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311–4320 (2008).
Google Scholar
Silva, I. A. et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71, 3991–4001 (2011).
Google Scholar
Gao, M. Q. et al. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29, 2672–2680 (2010).
Google Scholar
Kawazoe, A. et al. Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharm. 85, 855–862 (2020).
Google Scholar
Kahana, A. et al. Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: the VISORB trial. Oncologist 26, e1240–e1249 (2021).
Google Scholar
Brown, J. R. et al. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight 5, e133247 (2020).
Google Scholar
Bowles, D. W. et al. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral. Oncol. 53, 74–79 (2016).
Google Scholar
Hu, J. L. et al. A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clin. Cancer Res. 28, 689–696 (2022).
Google Scholar
Catenacci, D. V. et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J. Clin. Oncol. 33, 4284–4292 (2015).
Google Scholar
Ranjan, T. et al. Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial. Cell Rep. Med. 4, 101025 (2023).
Google Scholar
Trucco, M. M. et al. A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Clin. Sarcoma Res. 8, 21 (2018).
Google Scholar
